The Company
The AI-driven company behind HelioLiver — detecting cancer early from a simple blood draw, built on a decade of multi-omics research.
The largest prospective, multicenter U.S. trial of its kind.
Read the announcement →The Product
HelioLiver™ LDT — a multi-analyte, epigenomic blood test for early detection of liver cancer (HCC) from a simple blood draw.
Stage I HCC detection — HelioLiver vs ultrasound (CLiMB trial).
See the evidence →For Providers
Surveil at-risk patients with a simple blood draw that fits your existing office workflow.
Set up your office with kits and TRF / EMR ordering.
Order Now →For Patients
Living with a liver condition such as cirrhosis or chronic hepatitis? Ask your doctor about HelioLiver LDT.
Find out if HelioLiver LDT is right for you.
Learn more →
Detect liver cancer earlier with a simple blood testHelioLiver™ LDT is an epigenomic blood test for liver cancer surveillance in high-risk patients. It analyzes cell-free DNA methylation together with protein tumor markers to detect HCC at its earliest, most treatable stages. In the CLiMB trial, it detected 4× more Stage I cancers than ultrasound.1
Clinical evidence
By combining the results of cell-free DNA methylation testing with data from protein tumor markers and other clinical information, HelioLiver LDT delivers superior performance characteristics when compared to traditional tests for hepatocellular carcinoma (HCC).
Higher sensitivity to detecting smaller cancerous tumors means catching liver cancer cases in early stages, when curative options are available.
HelioLiver vs. Ultrasound — CLiMB Trial Results1
CLiMB trial: prospective, blinded, multicenter US evaluation in patients with cirrhosis.
What is HelioLiver
HelioLiver is an epigenomic blood test that combines cell-free DNA methylation, protein tumor markers, and clinical context to support early HCC detection in high-risk patients.
Reads cancer-related DNA changes circulating in the blood.
Add a second layer of HCC signal alongside the methylation data.
Brings both together for a clear result in high-risk patients.
more effective than ultrasound at detecting Stage I HCC1
T1 HCC detection in the CLiMB trial1
sensitivity for tumours ≤ 2 cm1
Find your path
If you are a hepatologist, gastroenterologist, or oncologist, HelioLiver LDT can support liver cancer screening and HCC surveillance in high-risk patients. It is a blood test for liver cancer that uses a simple blood draw during a regular physician visit.
If you have cirrhosis or another liver cancer risk factor, ask your doctor about HelioLiver LDT for early HCC detection. Liver cancer screening is especially important for people at higher risk, including those with cirrhosis and chronic hepatitis-related liver disease.
Helio Genomics is focused on early cancer detection through a clinically grounded blood test platform for liver cancer. The company’s CLiMB study publication and broader market coverage support its positioning in liver cancer diagnostics.
Why it matters
Liver cancer is often diagnosed after it has already advanced. Finding it earlier can expand treatment options and improve outcomes.
Curative options may include resection, transplant, or localized therapy.
Treatment often focuses on systemic therapy and symptom management.
If you have cirrhosis, chronic hepatitis B or C, heavy alcohol use, or NAFLD, you may be at higher risk for HCC. AASLD recommends HCC surveillance about every 6 months for people with cirrhosis.3
Check If You're at High Risk →Simple process
Each provider is set up with an ordering process that fits their office workflow, either through TRF or EMR.
The HelioLiver Collection Kit includes the materials needed to collect and prepare serum and plasma samples from each patient.
A prepaid return shipping label is included in each test kit for easy shipping.
Average turnaround time is 10–14 days for each sample.
You’ll receive a Normal or Abnormal result to indicate the likelihood of HCC.
Partnerships
The technology
HelioLiver LDT combines cfDNA methylation, protein biomarkers, and clinical data to support early HCC detection in high-risk patients.
Cancer cells can create detectable methylation changes in blood.
Newsroom
The largest prospective, multicenter U.S. trial of its kind demonstrates superior sensitivity for early HCC detection.
Read the Publication →
Watch
Questions
Get started
4× more effective than ultrasound for Stage I HCC detection.1 The CLiMB study was published in the Journal of Hepatology.